Comparative analyses of published cost effectiveness models highlight critical considerations which are useful to inform development of new models

References

• Postma MJ, Jit M, Rozenbaum MH, et al. Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world. BMC Med. 2011;9(1):84.
   PubMed Web of Science ®Google Scholar
• Turner D, Raftery J, Cooper K, et al. The CHD challenge: comparing four cost-effectiveness models. Value Health. 2011;14(1):53–60.
   PubMed Web of Science ®Google Scholar
• Critchlow S, Hirst M, Akehurst R, et al. A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future. J Med Econ. 2017;20(2):129–139.
   PubMed Web of Science ®Google Scholar
• van Mastrigt GAPG, Hiligsmann M, Arts JJC, et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):689–704.
   PubMed Web of Science ®Google Scholar
• Wijnen BFM, Van Mastrigt G, Redekop WK, et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):723–732.
   PubMed Web of Science ®Google Scholar
• Thielen FW, Van Mastrigt G, Burgers LT, et al. How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):705–721.
   PubMed Web of Science ®Google Scholar
• Green C. Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis. PharmacoEconomics. 2007;25(9):735–750.
   PubMed Web of Science ®Google Scholar
• Evers SM, Hiligsmann M, Adarkwah CC. Risk of bias in trial-based economic evaluations: identification of sources and bias-reducing strategies. Psychol Health. 2015;30(1):52–71.
   PubMed Web of Science ®Google Scholar
• Welte R, Feenstra T, Jager H, et al. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics. 2004;22(13):857–876.
   PubMed Web of Science ®Google Scholar
• Daniel Mullins C, Onwudiwe NC, Branco de Araújo GT, et al. Guidance document: global pharmacoeconomic model adaption strategies. Value Health Reg Issues. 2014;5:7–13.
   PubMedGoogle Scholar
• Anderson R, Schemilt I. Chapter 3: The role of economic perspectives and evidence in systematic review. In: Shemilt I, Mugford M, Vale L, et al., editors. Evidence-based decision and economics: health care, social welfare, education and criminal justice. Oxford: Wiley-Blackwell; 2010. p. 23–39.
   Google Scholar
• Squires H, Chilcott J, Akehurst R, et al. A framework for developing the structure of public health economic models. Value Health. 2016;19(5):588–601.
   PubMed Web of Science ®Google Scholar
• Pignone M. Challenges in systematic reviews of economic analyses. Ann Intern Med. 2005;142(12_Part_2):1073–1079.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Barbieri M, Wong JB. Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference? Med Decis Making. 2005;25(5):520–533.
   PubMed Web of Science ®Google Scholar
• Drummond MF. Methods for the economic evaluation of health care programmes. 3rd ed. 2011. Oxford: Oxford medical publications.
   Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force 1. Value Health. 2012;15(6):796–803.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. Modeling good research practices overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force 1. Med Decis Making. 2012;32(5):667–677.
   PubMed Web of Science ®Google Scholar
• Roberts M, Russell LB, Paltiel AD, et al. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force 2. Value Health. 2012;15(6):804–811.
   PubMed Web of Science ®Google Scholar
• Roberts M, Russell LB, Paltiel AD, et al. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force 2. Med Decis Making. 2012;32(5):678–689.
   PubMed Web of Science ®Google Scholar
• Bank W. World Bank Database. 2017. [cited 2018 Aug 30]; Available from: https://data.worldbank.org/.
   Google Scholar
• Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001;134(6):440–450.
   PubMed Web of Science ®Google Scholar
• Corzillius M, Mühlberger N, Sroczynski G, et al. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV. Antivir. Ther. 2004;9(1):27–36.
   PubMed Web of Science ®Google Scholar
• Sendi P, for the Swiss HIV Cohort Study, Günthard HF, Simcock M, et al. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure. PLoS One. 2007;2(1):e173.
   PubMed Web of Science ®Google Scholar
• Levison JH, Wood R, Scott CA, et al. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa. Clin Infect Dis. 2013;56(4):587–597.
   PubMed Web of Science ®Google Scholar
• Phillips A, Cambiano V, Nakagawa F, et al. Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings. PLoS One. 2014;9(10):e109148.
   PubMed Web of Science ®Google Scholar
• Phillips AN, Sabin C, Pillay D, et al. HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. HIV Med. 2007;8(8):536–546.
   PubMed Web of Science ®Google Scholar
• Phillips AN, Pillay D, Miners AH, et al. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet. 2008;371(9622):1443–1451.
   PubMed Web of Science ®Google Scholar
• Phillips AN, Pillay D, Garnett G, et al. Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. Aids. 2011;25(6):843–850.
   PubMed Web of Science ®Google Scholar
• Cambiano V, Bertagnolio S, Jordan MR, et al. Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings. J Infect Dis. 2013;207(suppl_2):S57–S62.
   PubMedGoogle Scholar
• Cambiano V, Bertagnolio S, Jordan MR, et al. Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation. Aids. 2014;28 (Suppl 1):S15–S23.
   PubMedGoogle Scholar
• Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 1999;353(9156):863–868.
   PubMed Web of Science ®Google Scholar
• Haupts S, Swiss HIV Cohort Study, Ledergerber B, Böni J, et al. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antivir. Ther. 2003;8(5):443–454.
   PubMed Web of Science ®Google Scholar
• Mellors JW. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946–954.
   PubMed Web of Science ®Google Scholar
• Corzillius M, Mühlberger N, Sroczynski G, et al. Health Technology Assessment: Wertigkeit des Einsatzes der genotypischen und phänotypischen HIV-Resistenzbestimmung im Rahmen der Behandlung von HIV-infizierten Patienten [Health Technology Assessment: evaluating the medical benefits, costs, and cost-effectiveness of using genotypic and phenotypic antiretroviral resistance testing for the treatment of HIV-infected patients]. 2003.
   Google Scholar
• Freedberg KA. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA. 1998;279(2):130–136.
   PubMed Web of Science ®Google Scholar
• Torrance G. Social preferences for health states: an empirical evaluation of three measurement techniques. Socio-Eco Plan Sci. 1976;10(3):129–136.
   Web of Science ®Google Scholar
• Zinkernagel C, Ledergerber B, Battegay M, et al. Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study. Aids. 1999;13(12):1587–1589.
   PubMed Web of Science ®Google Scholar
• Mrus JM, Yi MS, Freedberg KA, et al. Utilities derived from visual analog scale scores in patients with HIV/AIDS. Med Decis Making. 2003;23(5):414–421.
   PubMed Web of Science ®Google Scholar
• WHO. World Health Organisation HIV Drug Resistance Report 2019. 2019.
   Google Scholar
• Murphy RA, Sunpath H, Lu Z, et al. South Africa Resistance Cohort Study Team. Outcomes after virologic failure of first-line ART in South Africa. AIDS. 2010;24(7):1007–1012.
   PubMed Web of Science ®Google Scholar
• Hill AM, Venter F. The unexpected success of NRTIs in second-line treatment. Lancet Infect Dis. 2018;18(1):3–5.
   PubMed Web of Science ®Google Scholar
• Siedner MJ, Bwana MB, Moosa MS, et al. The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates. HIV Clin Trials. 2017;18(4):149–155.
   PubMed Web of Science ®Google Scholar